ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News $27.74 -0.38 (-1.35%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$27.60▼$28.6550-Day Range$22.22▼$28.1952-Week Range N/AVolume3.81 million shsAverage VolumeN/AMarket Capitalization$1.81 billionAssets Under Management$1.76 billionDividend YieldN/ANet Expense Ratio0.75% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings About ARK Genomic Revolution ETF (BATS:ARKG)The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.Read More ARKG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARKG ETF News HeadlinesNovember 28, 2023 | za.investing.comARK boosted its stake in this TechBio company by 45% on MondayOctober 24, 2023 | msn.comModerna’s stock snaps record losing streak as Cathie Wood’s ETF boosts stake by more than $4 millionDecember 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 2, 2023 | msn.comCathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?September 12, 2023 | markets.businessinsider.comCathie Wood's Ark Invest Bumps Up Stake In This Chipmaker After Selling $10M Worth Of Nvidia Last WeekAugust 25, 2023 | benzinga.comCathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI SurgeAugust 23, 2023 | finance.yahoo.com‘Thematic Fatigue’ Hobbles Once-Hot Slice of ETFs With OutflowsJuly 11, 2023 | forbes.comElon Musk, Steve Wozniak Sound Alarm On Dangerous AIDecember 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. July 2, 2023 | msn.comARKG: Outperforming XBI, Reasonably Valued With Technical Upside Potential In 2HSee More Headlines Receive ARKG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerARK Fund NameARK Genomic Revolution ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:ARKG Inception Date10/31/2014 Fund ManagerCatherine Wood WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings42 Fund Statistics Assets Under Management$1.79 billion Average Daily Volume$3.12 million Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorThe Bank of NewYork Mellon Corporation AdvisorARK Investment Management LLC CustodianThe Bank of NewYork Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of NewYork Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume6,463 Put Options1,890 Call Options4,573 Miscellaneous Outstanding Shares65,100,000Beta1.50 Creation Unit50,000 Creation Fee$500.00 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report ARK Genomic Revolution ETF ExpensesTypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.75%0.57%0.53%0.55%0.51%Other Expenses0.00%0.76%0.53%0.51%0.57%Total Expense0.75%0.73%0.69%0.68%0.69%Fee Waiver0.00%-0.78%-0.54%-0.36%-0.58%Net Expense0.75%0.60%0.59%0.62%0.57% ARK Genomic Revolution ETF (ARKG) Holdings & ExposureTop 10 ARKG HoldingsExact Sciences(NASDAQ:EXAS)Holding Weight: 9.79%Schrödinger(NASDAQ:SDGR)Holding Weight: 7.61%Pacific Biosciences of California(NASDAQ:PACB)Holding Weight: 6.11%Teladoc Health(NYSE:TDOC)Holding Weight: 4.60%Ginkgo Bioworks(NYSE:DNA)Holding Weight: 4.47%Ionis Pharmaceuticals(NASDAQ:IONS)Holding Weight: 4.37%Adaptive Biotechnologies(NASDAQ:ADPT)Holding Weight: 3.80%Accolade(NASDAQ:ACCD)Holding Weight: 3.71%CRISPR Therapeutics(NASDAQ:CRSP)Holding Weight: 3.53%CareDx(NASDAQ:CDNA)Holding Weight: 3.36%ARKG Sector ExposureARKG Industry ExposureFull Holdings Details Similar ETFsSPDR S&P Kensho New Economies Composite ETFNYSEARCA:KOMPETFMG Prime Cyber Security ETFNYSEARCA:HACKWisdomTree Emerging Markets ex-State-Owned Enterprises FundNYSEARCA:XSOEiShares Paris-Aligned Climate MSCI USA ETFNASDAQ:PABUARK Next Generation Internation ETFNYSEARCA:ARKWInstitutional OwnershipBanque Pictet & Cie SABought 9,473 shares on 11/27/2023Ownership: 0.015%Walleye Trading LLCSold 600 shares on 11/21/2023Ownership: 0.000%Comerica BankBought 6,834 shares on 11/21/2023Ownership: 0.010%Wolverine Trading LLCBought 8,300 shares on 11/16/2023Ownership: 0.000%Creative PlanningSold 1,244 shares on 11/16/2023Ownership: 0.020%View All Institutional Transactions ARKG ETF - Frequently Asked Questions How have ARKG shares performed in 2023? ARK Genomic Revolution ETF's stock was trading at $28.23 on January 1st, 2023. Since then, ARKG shares have decreased by 1.7% and is now trading at $27.74. View the best growth stocks for 2023 here. What does ARKG invest in? ARK Genomic Revolution ETF is a equity fund issued by ARK. ARKG focuses on theme investments. The fund's investments total to approximately $1.79 billion assets under management. What stocks does ARK Genomic Revolution ETF hold? ARKG invests in 42 holdings. Some of the stocks in their portfolio include Exact Sciences (EXAS), Schrödinger (SDGR), Pacific Biosciences of California (PACB), Teladoc Health (TDOC), Ginkgo Bioworks (DNA), Ionis Pharmaceuticals (IONS), Adaptive Biotechnologies (ADPT), Accolade (ACCD), CRISPR Therapeutics (CRSP) and CareDx (CDNA). What is the management fee for ARK Genomic Revolution ETF? ARK Genomic Revolution ETF's management fee is 0.75% and has no other recorded expenses or fee waivers. The net expense ratio for ARKG is 0.75%. Who are ARK Genomic Revolution ETF's major shareholders? ARK Genomic Revolution ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (4.93%), LPL Financial LLC (1.42%), Citigroup Inc. (0.99%), UBS Group AG (0.76%), Commonwealth Equity Services LLC (0.67%) and Affinity Asset Advisors LLC (0.00%). How do I buy shares of ARK Genomic Revolution ETF? Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (BATS:ARKG) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.